Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15324248 | 0.80 | BRD4 (0.43) | AKR1B1BRD4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25387941 | 0.80 | GRIA1 (0.46) | BRD4CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL28923537 | 0.77 | BRD4 (0.49) | BRD4ALDH1A1KDM4ESMN1; SMN2PDE3B | |
| SCHEMBL29267749 | 0.77 | BRD4 (0.47) | BRD4CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL9143227 | 0.76 | CYP1A2 (0.39) | AKR1B1CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL56146 | 0.75 | ALDH1A1 (0.51) | AKR1B1BRD4CYP1A2ALDH1A1KDM4E | |
| SCHEMBL755117 | 0.75 | BRD4 (0.49) | AKR1B1BRD4ALDH1A1PDE3BPDE3A | |
| SCHEMBL13672082 | 0.74 | AKR1B1 (0.39) | AKR1B1BRD4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7000113 | 0.73 | PARP1 (0.44) | AKR1B1ALDH1A1PDE3BPDE3ACA12 | |
| SCHEMBL303131 | 0.72 | MMP12 (0.44) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-2785709-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-1984345-B9 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| EP-1984345-B1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-0432893-A2 | Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | AKR1B1 132/4885BRD4 203/4885CYP1A2 164/4885 |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | NR3C2, MC2R, NR3C1 | AKR1B1 132/4885BRD4 203/4885CYP1A2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.